Drug pricing has emerged arsenic a cardinal taxable to ticker for pharmaceutical companies and investors successful 2025. As President Donald Trump pushes for little medicine prices for Americans, the assemblage is facing further pricing unit from a Biden-era instrumentality called the Inflation Reduction Act.
The IRA, voted into instrumentality successful 2022, allows the Centers for Medicare & Medicaid Services (CMS) to negociate prices for a fig of drugs each twelvemonth for patients successful Medicare, the national wellness security programme for seniors. It's present making waves besides crossed the Atlantic.
While these changes are taking spot firmly successful the U.S., pharmaceutical companies crossed the globe are uncovering themselves progressively exposed to the American market.
A fig of European companies person announced sizeable U.S. investments to placate Trump and his assertive tariff agenda, portion AstraZeneca is moving toward another nonstop listing connected the NYSE to pat into the deeper pockets of U.S. superior markets. Meanwhile, Novo Nordisk has cited a nonaccomplishment to woody with changes successful the U.S. marketplace arsenic portion of the crushed for recent leadership changes.
Late Tuesday, the CMS announced recently negotiated prices for 15 blockbuster drugs from 2027, including Novo Nordisk's mega bestseller Ozempic which volition spot a 71% discount to its database price.
Among different European pharma giants, AstraZeneca's crab cause Calquence volition look a 40% discount, portion GSK's lung illness medicines Trelegy and Breo with 73% and 83% discount, respectively.
Overall, discounts ranged betwixt 38% and 85%, with estimated savings of astir $8.5 billion, 36% little than caller yearly spending.
"Whether done the Inflation Reduction Act oregon President Trump's Most Favored Nation policy, this is what serious, fair, and disciplined dialog looks like," said CMS Deputy Administrator Chris Klomp successful a statement.
A GSK spokesperson said they were pleased with the agreement. "We powerfully judge successful the worth of some Trelegy and Breo and stay committed to moving with CMS."
Novo, connected the different hand, was critical. "We proceed to person superior concerns astir the Inflation Reduction Act's interaction connected patients and stay opposed to authorities terms setting," a spokesperson told CNBC successful emailed comments. "We person seen that authorities terms mounting has not translated to little out-of-pocket costs for patients and tin pb to a nonaccomplishment of sum for medications and higher security premiums," they added.
A cardinal market
The U.S. is simply a cardinal marketplace for astir large-cap pharma companies, mostly owed to the importantly higher prices for branded medicines. In the archetypal 9 months of 2025, 56% of Novo's full income originated successful the U.S. Meanwhile, AstraZeneca logged 42% of merchandise income successful the U.S. and GSK immoderate 52%, implicit the aforesaid period.
Prescription cause prices are astir 3 times higher successful the U.S. compared to different affluent countries, a 2024 study by RAND found.
"The [IRA price] cuts were a small higher than past year, which I deliberation radical were expecting," Barclays expert Emily Field told CNBC. "It doesn't look similar determination was immoderate surprises astatine all," she added.
Muted shares besides indicated that the result of the negotiations was mostly expected. AstraZeneca and GSK roseate little than 1% each successful day trading.
Novo shares however, ended the time 4.7% higher. Semaglutide, sold arsenic Ozempic for diabetes and Wegovy for value loss, volition from 2027 beryllium priced astatine $274 for Medicare patients, down from a erstwhile database terms of $959. That said, Medicare plans already get ample discounts connected companies' database prices, but those rates aren't typically disclosed.
CMS is owed to people its database of 15 drugs selected for negotiations for 2028 by February 1, 2026.
A Trump priority
The IRA terms negotiations are, however, not the main interest for companies, Field said, noting however it's becoming a better-understood and predictable process. "What radical are overmuch much disquieted astir is further directions that MFN could go… if they determine to bash thing different," she said.
Trump has made it a precedence to rein successful U.S. cause costs and successful May, signed an executive order to instrumentality alleged Most Favored Nation pricing, meaning U.S. prices would beryllium tied to little ones paid abroad.
Lower prices successful the U.S. could person a melodramatic effect connected companies' apical and bottommost lines, but companies are uncovering ways to mitigate the interaction by making deals with the Trump medication to voluntarily little definite prices, arsenic good arsenic pledge investments successful U.S. manufacturing to debar tariffs.
Novo, AstraZeneca and GSK shares twelvemonth to date.
Earlier this month, Trump announced deals with Novo and rival Eli Lilly to slash prices of value nonaccomplishment drugs for Medicare and Medicaid beneficiaries successful 2026, arsenic good arsenic offering them straight to consumers astatine a discount done the TrumpRx.gov website. Under the agreement, starting doses of Novo's Wegovy and Lilly's Zepbound volition beryllium $350 per period and inclination down to $245 per period implicit a 2 years.
While reduced pricing volition deed sales, measurement gains from opening up wide entree for obesity drugs could offset that headwind, BMO analysts noted.
Last week, Novo besides announced it is lowering prices of Ozempic and Wegovy to $349 per period from $499 for patients paying out-of-pocket, pursuing unit from Trump.
Other companies including AstraZeneca and U.S.-based Pfizer person besides announced deals with the Trump medication to chopped cause prices.
English (US) ·